Home | Contact Us | FAQ | Search & Site Map | Link to Us
Sign In | Join | Other 45 Sites in Network
Home
Discussion Groups
General
GeneralCardiologyVisionDentistryPharmacyLaboratoryNutritionAlternative
Diseases and Disorders
AIDSAlzheimer'sArthritisAsthmaCancerBreast CancerDiabetesEpilepsyGlaucomaHepatitisHerpesLupusProstate BPHProstate CancerProstatitisSinusitisTinnitus

Medical Forum / Diseases and Disorders / Arthritis / May 2007

Tip: Looking for answers? Try searching our database.

Osteoporosis and bisphosphonates

Thread view: 
Enable EMail Alerts  Start New Thread
Thread rating: 
ironjustice@aol.com - 10 May 2007 14:54 GMT
Osteoporosis Treatment -- Without Estrogen
Libraries
Medical News   Keywords
POSTMENOPAUSAL, OSTEOPOROSIS
Contact Information

Available for logged-in reporters only
Description

A class of drugs called bisphosphonates has become the new mainstay
treatment for postmenopausal women diagnosed with osteoporosis in the
post-hormone-replacement era. Taking just one pill a week, or even one
a month, may prevent, slow or stop the breakdown and progress of this
bone-thinning condition, according to the May issue of Mayo Clinic
Women's HealthSource.

Newswise - A class of drugs called bisphosphonates has become the new
mainstay treatment for postmenopausal women diagnosed with
osteoporosis in the post-hormone-replacement era. Taking just one pill
a week, or even one a month, may prevent, slow or stop the breakdown
and progress of this bone-thinning condition, according to the May
issue of Mayo Clinic Women's HealthSource.

An estimated 10 million Americans, mostly women, have osteoporosis,
where bones become weak and highly prone to fractures. Millions more
have low bone density (osteopenia), which can increase the risk of
fractures.

Bone -- a living tissue -- is constantly remodeling, with old bone
breaking down and new bone replacing it. Bisphosphonates work by
slowing the breakdown and reabsorption of old bone, an ongoing process
that accelerates as estrogen levels fall during the first few years
after menopause. By slowing the process, bisphosphonates help preserve
bone density and reduce the risk of fractures.

Estrogen once was commonly prescribed to reduce bone loss. But when
the landmark Women's Health Initiative Study, released in 2002, showed
that long-term estrogen use increased the risk of breast cancer, heart
attacks, strokes and blood clots, hormone therapy fell out of favor.

Bisphosphonates have filled the void and perform as well as estrogen
in preventing bone loss. Bisphosphonates available to treat
osteoporosis include alendronate (Fosamax), ibandronate (Boniva) and
risedronate (Actonel).

Patients should talk with a doctor about the best ways to prevent and
treat osteoporosis. Bisphosphonates have potential side effects, most
commonly heartburn and abdominal pain caused by irritation of the
esophagus or stomach. Even when taking medications, patients should
take steps to protect bones, including consuming adequate calcium and
vitamin D; engaging in regular weight-bearing exercise such as walking
and weight training; and avoiding smoking and excessive use of
alcohol.

--------------------------------------------------------------------------------

© 2007 Newswise.  All Rights Reserved.
--------------------------------------------------------------------------------

http://tinyurl.com/4ustm

Bisphosphonates

Bisphosphonates are a family of drugs used to prevent and treat
osteoporosis. There are three bisphosphonates currently approved for
use in Canada: alendronate (Fosamax ®), etidronate (Didrocal ®) and
risedronate (Actonel ®).

---------------------------------------------------------------------------­----------

<<snip>>
Bisphosphonates have antioxidant properties as iron chelators
<<snip>>

Antioxidant effect of bisphosphonates and simvastatin on chondrocyte
lipid peroxidation.
Dombrecht EJ, De Tollenaere CB, Aerts K, Cos P, Schuerwegh AJ, Bridts
CH, Van Offel JF, Ebo DG, Stevens WJ, De Clerck LS
Biochem Biophys Res Commun. 2006 Jul 28;

The objective of this study was to evaluate the effect of
bisphosphonates (BPs) and simvastatin on chondrocyte lipid
peroxidation. For this purpose, a flow cytometrical method using
C11-BODIPY(581/591) was developed to detect hydroperoxide-induced
lipid
peroxidation in chondrocytes. Tertiary butylhydroperoxide (t-BHP)
induced a time and concentration dependent increase in chondrocyte
lipid peroxidation. Addition of a Fe(2+)/EDTA complex to t-BHP or
hydrogen peroxide (H(2)O(2)) clearly enhanced lipid peroxidation. The
lipophilic simvastatin demonstrated a small inhibition in the
chondrocyte lipid peroxidation. None of three tested BPs (clodronate,
pamidronate, and risedronate) had an effect on chondrocyte lipid
peroxidation induced by t-BHP. However, when Fe(2+)/EDTA complex was
added to t-BHP or H(2)O(2), BPs inhibited the lipid peroxidation
process varying from 25% to 58%. This study demonstrates that BPs
have
antioxidant properties as iron chelators, thereby inhibiting the
chondrocyte lipid peroxidation. These findings add evidence to the
therapeutic potential of bisphosphonates and statins in rheumatoid
arthritis.

---------------------------------------------------------------------------­----------

Age-associated Iron Accumulation in Bone: Implications for
Postmenopausal Osteoporosis and a New Target for Prevention and
Treatment by Chelation.
Liu G, Men P, Kenner GH, Miller SC
Biometals. 2006 May 11;

Iron accumulation in tissues is believed to be a characteristic of
aged

humans and a risk factor for some chronic diseases. However, it is
not
known whether age-associated iron accumulation is part of the
pathogenesis of postmenopausal osteoporosis that affects
approximately
one out three women worldwide. Here, we confirmed that this
accumulation of iron was associated with osteopenia in ovariectomized
(OVX) rats (a model of peri- and postmenopausal osteoporosis due to
estrogen deficiency). To further investigate whether the increased
iron

level plays a causal role in the onset of bone loss, we treated OVX
rats with an orally active and bone targeted chelator that prevented
iron accumulation in their skeletal tissues. The results showed that
this treatment mitigated the loss of bone mass and the deterioration
of

bone micro-architecture. We also found that one possible mechanism of
the protective action of iron chelation was to significantly reduce
bone resorption. Thus, these findings provide a novel target and a
potentially useful therapeutic strategy for the prevention and
treatment of postmenopausal osteoporosis and perhaps other age-
related
diseases.

Who loves ya.
Tom

Jesus Was A Vegetarian!
http://jesuswasavegetarian.7h.com

Man Is A Herbivore!
http://tinyurl.com/a3cc3

DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk
Juhana Harju - 10 May 2007 15:38 GMT
: Age-associated Iron Accumulation in Bone: Implications for
: Postmenopausal Osteoporosis and a New Target for Prevention and
[quoted text clipped - 27 lines]
: related
: diseases.

Iron restriction has a negative effect on bone:

http://tinyurl.com/2clp9n

http://tinyurl.com/2zyzrq

Signature

Juhana

iceman458458@yahoo.com - 13 May 2007 15:54 GMT
This makes me wonder if any naturally occurring substitutes exist for
bisphosphonates which someone can just pop and gain the same benefits.
Is this just Phosphate in a fancy wrapping?
ironjustice - 14 May 2007 14:11 GMT
>>On May 13, 7:54 am, iceman458...@yahoo.com wrote:
This makes me wonder if any naturally occurring substitutes exist for
bisphosphonates which someone can just pop and gain the same
benefits.
Is this just Phosphate in a fancy wrapping?<<

If you notice the  .. phosphate groups / myo-inositol hexaphosphate
seem to be SUPERIOR to the bisphosponate .. etidronate.

<<snip>>
myo-inositol hexaphosphate acts as an inhibitor of calcium salt
crystallization
<<snip>>

Life Sci. 2004 May 21;75(1):11-9.  Links
Dietary myo-inositol hexaphosphate prevents dystrophic calcifications
in soft tissues: a pilot study in Wistar rats.Grases F, Perello J,
Prieto RM, Simonet BM, Torres JJ.
Laboratory of Renal Lithiasis Research, Institute of Health Sciences
(IUNICS), University of Balearic Islands, Ctra. Valldemossa Km 7.5,
07071, Palma de Mallorca, Spain. fgrases@uib.es

Myo-inositol hexaphosphate (InsP6) is an abundant component of plant
seeds. It is also found in significant levels in blood and mammalian
tissues, but they are totally dependent on their dietary intake. In
the present paper, we describe studies on the effect of InsP6 on a
model of dystrophic calcification, which was chemically induced by
subcutaneous injection of a 0.1% KMnO4 solution. Male Wistar rats were
randomly divided into four groups for treatment over 31 days. A:
animals consuming a purified diet in which InsP6 was absent but to
which 1% of InsP6 (as sodium salt) was added. In this group, the InsP6
plasma levels (0.393 +/- 0.013 microM) were similar to those observed
in rats consuming a standard diet. B: animals consuming only the
purified diet in which InsP6 was absent. In this case the InsP6 plasma
levels decreased (0.026 +/- 0.006 microM); C: animals consuming the
same purified diet as group B but received daily subcutaneous
injections of 50 microg kg(-1) etidronate during the last 14 days. In
this case the InsP6 plasma levels were also very low (0.025 +/- 0.007
microM); D: animals consuming the same diet as group B but a 6% of
carob germ (InsP6 rich product) was added. The InsP6 plasma levels
(0.363 +/- 0.035 microM) were also similar to those observed in rats
consuming a standard diet. After 21 days plaque formation was induced.
Calcification plaques were allowed to proceed for 10 days, after which
the plaque material present was excised, dried and weighed. It was
found that the presence of myo-inositol hexaphosphate (phytate) in
plasma at normal concentrations (0.3-0.4 microM) clearly inhibited the
development of dystrophic calcifications in soft tissues. These
results demonstrates that myo-inositol hexaphosphate acts as an
inhibitor of calcium salt crystallization.

PMID: 15102518 [PubMed - indexed for MEDLINE]

Who loves ya.
Tom

Jesus Was A Vegetarian!
http://jesuswasavegetarian.7h.com

Man Is A Herbivore!
http://tinyurl.com/a3cc3

DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk
iceman458458@yahoo.com - 24 May 2007 05:57 GMT
Phytates. Isn't that supposed to be those chemicals present in seeds
that we are supposed to get rid of, by soaking the seeds or the beans
before cooking them so that no more phytates remain and there will be
no interference in absorbtion of nutrients in the gut after the
phytates are gone? Phytates block absorbtion of minerals and
nutrients. I thought phytates were the bad guys, oats have a huge
amount of them.
 
Sign In
Join
My Latest Posts
My Monitored Threads
My Blog
My Photo Gallery
My Profile
My Homepage

Start New Thread
Enable EMail Alerts
Rate this Thread



©2008 Advenet LLC   Privacy Policy - Terms of Use
This website includes both content owned or controlled by Advenet as well as content owned or controlled by third parties.